Metabolic Consequences of CPT-1 Deficiency

This study has been completed.
Sponsor:
Collaborator:
Alaska Department of Health and Social Services
Information provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ClinicalTrials.gov Identifier:
NCT00653666
First received: April 3, 2008
Last updated: February 24, 2010
Last verified: February 2010
  Purpose

The purpose of this study is to learn more about how long children with CPT-1 deficiency can wait between meals without developing low blood sugar or symptoms of low blood sugar. The other purpose is to learn more about how much fat is stored in the liver of a child with CPT-1 deficiency.


Condition Intervention
Carnitine Palmitoyl Transferase Type 1A (CPT1A) Deficiency
Other: Medically supervised fasting

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Metabolic Consequences of CPT1A Deficiency in Alaska Native Children

Resource links provided by NLM:


Further study details as provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):

Primary Outcome Measures:
  • To compare body composition, liver and muscle lipid content, and liver function of Alaska Native children with CPT1A deficiency, with similar measures in their unaffected siblings. [ Time Frame: February 2009 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To characterize the metabolic response of Alaska Native children with CPT1A deficiency to fasting, [ Time Frame: February 2009 ] [ Designated as safety issue: No ]

Estimated Enrollment: 12
Study Start Date: October 2007
Study Completion Date: February 2009
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Other: Medically supervised fasting
    Metabolic fasting studies will be conducted over an 18-hour period or until blood glucose is < 40 mg/dl. If the YSI reading is 40 mg/dl or less, at any time during the study, then a blood sample will be collected, and the fast terminated by giving D25W IV and then feeding orally.
Detailed Description:

With the advent of enhanced screening (via tandem mass spectroscopy, MS/MS), the Northwest Regional Newborn Screening Program (NWRNSP) has identified a high incidence of carnitine palmitoyl transferase type 1A (CPT1A) deficiency in Alaska Native infants. Since October of 2003 approximately 80 Alaska Native infants have been identified with this condition; previously only 30 published cases were known worldwide. All of the infants are homozygous for a c.1436C-T sequence variant in the CPT1A gene, which results in the substitution of a leucine for proline at amino acid position 479 (P479L), and an approximately 80% reduction of CPT1A activity (non-classic CPT1A deficiency) (7). The clinical implications of this very restricted level of enzyme activity are not known. However, patients with more severe reductions of CPT1A activity (as the result of other mutations) are known to be at high risk for hypoketotic hypoglycemia, liver dysfunction, and sudden unexplained death (1). Hepatomegaly with micro- and macro-vesicular steatosis is also common (16). Currently the treatment of Alaska Native infants and children with CPT1A deficiency is based on data from patients with more severe forms of CPT1A deficiency and other fatty acid oxidation (FAO) disorders. Our ultimate goal is to establish evidence-based guidelines for treatment of the form of CPT1A deficiency prevalent in the Alaska Native population. This pilot study addresses two specific questions and will provide the first glimpse of the physiologic effects of homozygosity for the c.1436C-T sequence variant in the CPT1A gene. These data will aid in the development of strategies for clinical management that can be evaluated in future prospective studies, and provide preliminary data required for applications for NIH funding for more in-depth characterization of the clinical consequences of this condition.

  Eligibility

Ages Eligible for Study:   3 Years to 5 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • CPT-1 deficiency
  • homozygous for the c.1436C-T sequence variant
  • greater than 6 kg
  • otherwise healthy
  • siblings must be free of CPT-1 deficiency but heterozygous for c.1436C-T sequence variant and otherwise healthy

Exclusion Criteria:

  • liver dysfunction
  • diabetes
  • renal disease
  • metal plate in body
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00653666

Locations
United States, Oregon
Oregon Health & Science University
Portland, Oregon, United States, 97239
Sponsors and Collaborators
Oregon Health and Science University
Alaska Department of Health and Social Services
Investigators
Principal Investigator: Melanie B. Gillingham, PhD Oregon Health and Science University
  More Information

No publications provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Melanie Gillingham, PhD, Oregon Health & Science University
ClinicalTrials.gov Identifier: NCT00653666     History of Changes
Other Study ID Numbers: CTRC1029 (completed)
Study First Received: April 3, 2008
Last Updated: February 24, 2010
Health Authority: United States: Federal Government

Keywords provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):
CPT1A
steatosis
deficiency
metabolic
response
fasting

ClinicalTrials.gov processed this record on July 23, 2014